{"id":"https://openalex.org/W2117751925","doi":"https://doi.org/10.1212/wnl.59.6.802","title":"Differential mechanisms of action of interferon-\u03b2 and glatiramer acetate in MS","display_name":"Differential mechanisms of action of interferon-\u03b2 and glatiramer acetate in MS","alternate_titles":[],"publication_year":2002,"publication_date":"2002-09-24","ids":{"openalex":"https://openalex.org/W2117751925","doi":"https://doi.org/10.1212/wnl.59.6.802","mag":"2117751925","pmid":"https://pubmed.ncbi.nlm.nih.gov/12349849"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.59.6.802","doi":"https://doi.org/10.1212/wnl.59.6.802","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.59.6.802","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2117751925"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080958470","display_name":"Voon Wee Yong","orcid":"https://orcid.org/0000-0002-2600-3563","observed_orcids":["https://orcid.org/0000-0002-2600-3563"]},"institutions":[{"id":"https://openalex.org/I168635309","display_name":"University of Calgary","ror":"https://ror.org/03yjb2x39","country_code":"CA","type":"education","lineage":["https://openalex.org/I168635309"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"V. Wee Yong","raw_affiliation_strings":["From the Departments of Oncology and Clinical Neurosciences, University of Calgary, Alberta, Canada","Department of Oncology and Clinical Neurosciences, University of Calgary, Alberta, Canada. vyong@ualgary.ca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Oncology and Clinical Neurosciences, University of Calgary, Alberta, Canada","institution_ids":["https://openalex.org/I168635309"]},{"raw_affiliation_string":"Department of Oncology and Clinical Neurosciences, University of Calgary, Alberta, Canada. vyong@ualgary.ca","institution_ids":["https://openalex.org/I168635309"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5080958470"],"corresponding_institution_ids":["https://openalex.org/I168635309"],"apc_list":null,"apc_paid":null,"fwci":12.593,"has_fulltext":false,"cited_by_count":270,"citation_normalized_percentile":{"value":0.99238298,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"59","issue":"6","first_page":"802","last_page":"808"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-beta","display_name":"interferon-beta","score":0.9129999876022339},{"id":"https://openalex.org/keywords/glatiramer-acetate","display_name":"glatiramer acetate","score":1.0},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9800000190734863},{"id":"https://openalex.org/keywords/blood-brain-barrier","display_name":"blood-brain barrier","score":0.7910000085830688},{"id":"https://openalex.org/keywords/leukocyte-migration","display_name":"leukocyte migration","score":0.7080000042915344},{"id":"https://openalex.org/keywords/bystander-suppression","display_name":"bystander suppression","score":0.9819999933242798},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.8989999890327454},{"id":"https://openalex.org/keywords/neuroinflammation","display_name":"neuroinflammation","score":0.6650000214576721},{"id":"https://openalex.org/keywords/autoimmunity","display_name":"autoimmunity","score":0.7599999904632568}],"concepts":[{"id":"https://openalex.org/C2778577042","wikidata":"https://www.wikidata.org/wiki/Q418274","display_name":"Glatiramer acetate","level":3,"score":0.9485276341438293},{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.7544885873794556},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.7368401885032654},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7093660831451416},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5791863203048706},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5043879747390747},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.48625147342681885},{"id":"https://openalex.org/C19106626","wikidata":"https://www.wikidata.org/wiki/Q230749","display_name":"Bystander effect","level":2,"score":0.48125478625297546},{"id":"https://openalex.org/C2780130043","wikidata":"https://www.wikidata.org/wiki/Q192360","display_name":"Autoimmunity","level":3,"score":0.44612425565719604},{"id":"https://openalex.org/C196822366","wikidata":"https://www.wikidata.org/wiki/Q270524","display_name":"Parenchyma","level":2,"score":0.43829184770584106},{"id":"https://openalex.org/C2778402981","wikidata":"https://www.wikidata.org/wiki/Q221694","display_name":"Blood\u2013brain barrier","level":3,"score":0.42223265767097473},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40976572036743164},{"id":"https://openalex.org/C529278444","wikidata":"https://www.wikidata.org/wiki/Q47273","display_name":"Central nervous system","level":2,"score":0.32023561000823975},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.22023892402648926},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17153432965278625},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.14323332905769348}],"mesh":[{"descriptor_ui":"D000068717","descriptor_name":"Glatiramer Acetate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000276","descriptor_name":"Adjuvants, Immunologic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1212/wnl.59.6.802","doi":"https://doi.org/10.1212/wnl.59.6.802","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.59.6.802","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},{"id":"pmid:12349849","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12349849","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W16312249","https://openalex.org/W1487241851","https://openalex.org/W1503190668","https://openalex.org/W1523977630","https://openalex.org/W1547955534","https://openalex.org/W1900649416","https://openalex.org/W1967733776","https://openalex.org/W1968168664","https://openalex.org/W1969508961","https://openalex.org/W1980647798","https://openalex.org/W1992401698","https://openalex.org/W2001262287","https://openalex.org/W2012656284","https://openalex.org/W2023030135","https://openalex.org/W2024061399","https://openalex.org/W2040740602","https://openalex.org/W2043435915","https://openalex.org/W2043704221","https://openalex.org/W2044346839","https://openalex.org/W2045281561","https://openalex.org/W2046329404","https://openalex.org/W2052530361","https://openalex.org/W2058360762","https://openalex.org/W2060109120","https://openalex.org/W2060979547","https://openalex.org/W2063986567","https://openalex.org/W2066124230","https://openalex.org/W2069947868","https://openalex.org/W2070632833","https://openalex.org/W2079849225","https://openalex.org/W2083770877","https://openalex.org/W2084510174","https://openalex.org/W2086196933","https://openalex.org/W2093471482","https://openalex.org/W2098801818","https://openalex.org/W2117976722","https://openalex.org/W2120203388","https://openalex.org/W2120819751","https://openalex.org/W2124795017","https://openalex.org/W2127671643","https://openalex.org/W2128340726","https://openalex.org/W2130949787","https://openalex.org/W2150733412","https://openalex.org/W2157600853","https://openalex.org/W2160866171","https://openalex.org/W2163113037","https://openalex.org/W2171907184","https://openalex.org/W2325038063","https://openalex.org/W4244028742","https://openalex.org/W4366064463"],"related_works":["https://openalex.org/W2111468824","https://openalex.org/W2044242440","https://openalex.org/W2094772849","https://openalex.org/W2127671643","https://openalex.org/W3169337332","https://openalex.org/W2156038982","https://openalex.org/W2132024098","https://openalex.org/W2009161521","https://openalex.org/W2724391652","https://openalex.org/W4384923756"],"abstract_inverted_index":{"Interferon-beta":[0,32],"and":[1,40],"glatiramer":[2],"acetate":[3],"(GA)":[4],"are":[5,78],"the":[6,14,37,42,48,57,68,87,92],"two":[7],"main":[8],"groups":[9],"of":[10,16,44,83,95],"drugs":[11],"used":[12],"in":[13],"treatment":[15],"MS.":[17],"Notably,":[18],"while":[19],"both":[20],"ultimately":[21],"decrease":[22,71],"CNS":[23,69,88],"inflammation,":[24],"they":[25],"do":[26],"so":[27],"by":[28],"very":[29],"different":[30],"mechanisms.":[31],"has":[33,53],"potent":[34],"activity":[35],"at":[36,56],"blood-brain":[38,58],"barrier":[39],"impairs":[41],"trafficking":[43],"inflammatory":[45],"cells":[46],"into":[47],"CNS.":[49],"In":[50],"contrast,":[51],"GA":[52],"negligible":[54],"effect":[55],"barrier,":[59],"allowing":[60],"GA-specific":[61],"T":[62],"helper":[63],"2":[64],"lymphocytes":[65,85],"to":[66,70],"enter":[67],"inflammation":[72],"through":[73,98],"bystander":[74],"suppression.":[75],"Other":[76],"differences":[77],"also":[79],"emphasized.":[80],"The":[81],"presence":[82],"GA-reactive":[84],"within":[86],"parenchyma":[89],"may":[90],"have":[91],"additional":[93],"benefit":[94],"conferring":[96],"neuroprotection":[97],"protective":[99],"autoimmunity.":[100]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2117751925","counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":12},{"year":2014,"cited_by_count":15},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
